Impact of Tumor Treating Fields on the Survival of Japanese Patients with Newly Diagnosed Glioblastoma: A Multicenter, Retrospective Cohort Study
Masayuki Kanamori,Shunsuke Tsuzuki,Ichiyo Shibahara,Kuniaki Saito,Yoshiteru Shimoda,Kazuhiro Tanaka,Shigeru Yamaguchi,Manabu Natsumeda,Tomoo Matsutani,Mitsuto Hanihara,Mitsutoshi Nakada,Jun-Ichiro Kuroda,Masahide Matsuda,Koji Yoshimoto,Ushio Yonezawa,Yukihiko Sonoda,Koji Takano,Hajime Yonezawa,Yoshihiro Otani,Yukiko Nakahara,Masashi Uchida,Masahiro Nonaka,Yohei Mineharu,Yohei Kitamura,Shinji Yamashita,Takahiro Yamauchi,Yohei Miyake,Shoichi Deguchi,Takaaki Beppu,Kaoru Tamura,Shinichiro Koizumi,Yuichi Hirose,Kenichiro Asano,Ryo Hiruta,Manabu Kinoshita,Keisuke Miyake,Noriyuki Nakayama,Akihiro Inoue,Takahiro Ono,Takahiro Sasaki,Yukinori Akiyama,Shinjiro Fukami,Atsuo Yoshino,Yu Kawanishi,Taku Asanome,Takuhiro Yamaguchi,Masamichi Takahashi,Fumiyuki Yamasaki,Yoshiki Arakawa,Yoshitaka Narita
DOI: https://doi.org/10.1093/noajnl/vdae176
2024-01-01
Neuro-Oncology Advances
Abstract:Abstract Background The EF-14 clinical trial demonstrated the safety and efficacy of tumor treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify the current status, safety, and efficacy of TTFields in Japanese patients who meet the EF-14 inclusion criteria. Methods This was a multicenter retrospective cohort study. Background, treatment, and outcome data of patients who satisfied the inclusion criteria of the EF-14 trial were collected from 45 institutions across Japan. The rate, determinants, and current status of TTField use, including its safety and efficacy in terms of progression and survival, were retrospectively investigated. This study was conducted in accordance with the STROBE checklist. Results Among the 607 patients enrolled, 70 were excluded due to progressive disease during radiation and temozolomide therapy, age >80 years old, and Karnofsky Performance Status score of <70. Among the remaining 537 patients, 210 (39%) underwent TTField treatment. Multivariate analysis revealed younger age and spouse as a caregiver as significant factors for TTField use. The compliance rate of TTFields use exceeded 75% in 60% of patients, with a median TTField usage duration of 11 months. Skin disorders requiring medical treatment occurred in 56% of patients. Multivariate Cox proportional hazards analysis in the whole series and propensity score-matched analysis revealed that TTField use was not a prognostic factor for progression-free survival (PFS) or overall survival (OS). Conclusion TTField use did not have a substantial effect on either PFS or OS in Japanese patients with glioblastoma, despite compliance rates comparable to those observed in the EF-14.